Franauis Beaubien

François Beaubien is a Partner at Sectoral Asset Management, a Montréal-headquartered specialist manager founded in 2000 that invests exclusively in the global healthcare sector. The firm is 100% employee-owned, has roughly 20+ investment professionals (including several partners), and runs offices in Montréal, Geneva, and Hong Kong across public-equity strategies (Global Healthcare, Emerging Markets Healthcare, Small & Mid Cap Healthcare, Biotech) and private/venture healthcare funds.

Beaubien pairs a scientific background with finance credentials — he holds a Ph.D. (his academic research was in neuroscience, including published work on BDNF expression, striatal morphology, and motor behavior in the R6/2 mouse model of Huntington's disease, affiliated with Montréal research institutions) and an MBA in Finance from the University of British Columbia (2012–2014). He is also a CFA charterholder. This science-plus-finance profile is typical of Sectoral's team, most of whom hold advanced degrees in science, medicine, or engineering alongside CFA designations.

In his current role he helps manage healthcare equities globally and is active on the firm's private/venture side, where Sectoral typically leads or co-leads financings and takes board representation. He serves in board and/or board-observer capacities at portfolio companies, most notably joining the Board of Directors of Evommune in connection with its 2024 Series C, and holding a board role at Apnimed, a sleep-apnea therapeutics company.

• Invests through a healthcare-only lens — biotech, medtech, and diagnostics — reflecting Sectoral's two-decade specialization in the sector.
• On the private side, Sectoral's funds pursue two tracks: early-stage medtech (Series A / first institutional round, leading and taking board seats) via *Fonds Medtech Ventures*, and clinical-stage biotech and devices (Series B or later) via the *NEMO* strategy, where the firm "typically leads or co-leads investments and holds board seats."
• Seeks potentially disruptive therapeutic or diagnostic solutions with strong risk-adjusted return potential *and* meaningful patient/health impact — the firm frames its mandate as combining financial returns with societal health benefit.
• Prefers an active, governance-oriented posture — leading/co-leading rounds and taking board or observer seats rather than passive minority checks (as evidenced by Beaubien's own board roles at Evommune and Apnimed).
• Geographic scope is North America and Europe for the venture/private strategies.